Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy
Sponsor: Medical College of Wisconsin
Terminated
slow recruitment.
Other terminated trials from Medical College of Wisconsin
Other Cardiac Amyloidosis trials with similar outcome
Listed as NCT03333551, this PHASE4 trial focuses on Cardiac Amyloidosis and remains terminated or withdrawn. Sponsored by Medical College of Wisconsin, it has been updated 13 times since 2020, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Oct 2021 — Jun 2023 [monthly]
Recruiting PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE4
Status: Recruiting → Not Yet Recruiting
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE4
-
May 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medical College of Wisconsin
For direct contact, visit the study record on ClinicalTrials.gov .